These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22082083)

  • 1. Effects of immunosuppressive drugs on the cognitive functioning of renal transplant recipients: a pilot study.
    Martínez-Sanchis S; Bernal MC; Montagud JV; Candela G; Crespo J; Sancho A; Pallardó LM
    J Clin Exp Neuropsychol; 2011 Nov; 33(9):1016-24. PubMed ID: 22082083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
    Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clinical factors on psychosocial variables in renal transplant recipients.
    Liu H; Feurer ID; Dwyer K; Shaffer D; Pinson CW
    J Adv Nurs; 2009 Dec; 65(12):2585-96. PubMed ID: 19941545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative psychological factors predicting graft rejection in patients undergoing kidney transplant: a pilot study.
    Calia R; Lai C; Aceto P; Luciani M; Saraceni C; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1006-9. PubMed ID: 21620037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients.
    Sahin G; Akay OM; Kus E; Bal C; Yalcin AU; Gulbas Z
    Ren Fail; 2009; 31(2):111-7. PubMed ID: 19212907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
    Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
    J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom occurrence, symptom distress, and quality of life in renal transplant recipients.
    Zarifian A
    Nephrol Nurs J; 2006; 33(6):609-18; quiz 619. PubMed ID: 17219723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality of life following transplantation. The impact ofa new immunosuppressive substance].
    Lütkes P; Franke G; Witzke O; Zimmermann U; Kohnle M; Philipp T; Heemann U
    Zentralbl Chir; 1999; 124(2):90-4. PubMed ID: 10209841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
    Stock PG; Roland ME; Carlson L; Freise CE; Roberts JP; Hirose R; Terrault NA; Frassetto LA; Palefsky JM; Tomlanovich SJ; Ascher NL
    Transplantation; 2003 Jul; 76(2):370-5. PubMed ID: 12883195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gingival overgrowth in subjects under immunosuppressive regimens based on cyclosporine, tacrolimus, or sirolimus.
    Cota LO; Aquino DR; Franco GC; Cortelli JR; Cortelli SC; Costa FO
    J Clin Periodontol; 2010 Oct; 37(10):894-902. PubMed ID: 20618547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.